Modifier gene identification, prioritization and study
- Develop disease pathway maps for HD and various SCAs (in liaison with WP7 and WP10)
- Identify and characterise genes that modulate aggregation of polyglutamine and other neurotoxic proteins
- Test the genetic interaction in vivo between Parkin and mutant ataxin 3
